Archive | February, 2010
FDA Response to CPI-300′s NDA Anticipated Soon (NASDAQ:IGXT)
CPI-300 is a drug that has been developed by IntelGenx Corp. (NASDAQ:IGXT.OB) and its partner, Cary Pharmaceuticals, Inc, under the Collaborative Agreement signed by the two companies in 2007. The drug is used as an antidepressant with an increased strength and can be used to treat disorders associated with depression.
Continue reading...FDA Response to ODFS’s NDA Anticipated (NYSE:PRX)
4 February 2010 – 9:39 am PST
Comments Off
Strativa Pharmaceuticals is a subsidiary owned by the Par Pharmaceutical Companies, Inc. (NYSE:PRX), a specialty pharmaceutical company that is involved in the development, manufacturing and commercialization of both generic drugs and novel branded drugs.
Continue reading...FDA response on Autologel Sytem Expected Soon (AMEX:GTF)
4 February 2010 – 9:37 am PST
Comments Off
On August 7, 2009, Cytomedix, Inc. (NYSE AMEX:GTF) announced that it has submitted to, the United Sates of America’s toughest regulator, the Food and Drug Administration (FDA) a 510(K) for its AutoloGel™ Platelet Separation System.
Continue reading...FDA response on IL 13-PE expected on February 4, 2010 (NASDAQ:NEOL)
4 February 2010 – 9:30 am PST
On January 4, 2010, NeoPharm, Inc. (NASDAQ:NEOL.PK), a biopharmaceutical company that discovers, develops and markets drugs for treating patients suffering from cancer and other life threatening diseases, disclosed that it has submitted an investigational new drug application (IND) to the FDA. The application was submitted for the IL 13-PE38QQR (also called IL 13-PE for short), [...]
Continue reading...FDA Response Expected Expected Soon for Bovie (AMEX:BVX)
4 February 2010 – 9:28 am PST
Comments Off
On August 3, 2009, Bovie Medical Corporation (AMEX:BVX) announced that it has submitted a 510(K) to the FDA, for its ICON VS electrosurgical generator, in order to obtain pre-market approval. We hope the company will get a response from the FDA after 6 months, around February 3, 2010.
Continue reading...Complete Results of Phase 2 trial of Biomoda’s Lung Cancer Test Anticipated (NASDAQ:BMOD)
1 February 2010 – 10:29 am PST
Comments Off
Biomoda, Inc. (NASDAQ:BMOD.OB), whose headquarter is in Albuquerque, New Mexico, is a company that discovers and develops precise, safe and cheap in-vitro tests that diagnose cancer in the early stage – the period of time when it is most possible for treatment methods to cure the cancer or to stop the cancer from getting worse.
Continue reading...Article on Perifosone’s Phase 2 trial to be published (NASDAQ:KERX)
1 February 2010 – 10:26 am PST
Comments Off
KRX-0401 (which is more popularly known by its generic name perifosone) is an anti-cancer drug that has been discovered and developed by Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Keryx, which has its headquarters in the New York City, acquires, develops and commercializes pharmaceutical drugs that can cure or improve the conditions of people suffering from fatal diseases, [...]
Continue reading...
4 February 2010 – 9:46 am PST
Comments Off